Q2 2022 13F Holders as of 6/30/2022
-
Type / Class
-
Equity / COMMON-STOCK
-
Shares outstanding
-
72.2M
-
Number of holders
-
112
-
Total 13F shares, excl. options
-
58.1M
-
Shares change
-
+13.9M
-
Total reported value, excl. options
-
$1.63B
-
Value change
-
+$360M
-
Put/Call ratio
-
0.02
-
Number of buys
-
72
-
Number of sells
-
-50
-
Price
-
$28.10
Significant Holders of Zentalis Pharmaceuticals, Inc. - COMMON-STOCK (ZNTL) as of Q2 2022
144 filings reported holding ZNTL - Zentalis Pharmaceuticals, Inc. - COMMON-STOCK as of Q2 2022.
Zentalis Pharmaceuticals, Inc. - COMMON-STOCK (ZNTL) has 112 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 58.1M shares
of 72.2M outstanding shares and own 80.5% of the company stock.
Largest 10 shareholders include Matrix Capital Management Company, LP (9.2M shares), FMR LLC (7.78M shares), VANGUARD GROUP INC (4.49M shares), PRICE T ROWE ASSOCIATES INC /MD/ (4.3M shares), Avidity Partners Management LP (3.59M shares), BlackRock Inc. (3.24M shares), STATE STREET CORP (3.12M shares), TYBOURNE CAPITAL MANAGEMENT (HK) LTD (2.43M shares), VIKING GLOBAL INVESTORS LP (2.03M shares), and Decheng Capital Management III (Cayman), LLC (1.82M shares).
This table shows the top 112 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.